O'LearyJ., MuggiaF.M.: Camptothecins: a review of their development and schedules of administration.Eur J Cancer, 34: 1500–1508, 1998.
2.
CunninghamD., PyrhonenS., JamesR.D.: Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer.Lancet, 352: 1413–1418, 1998.
3.
RougierP., Van CustemE., BajettaE.: Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer.Lancet, 352: 1407–1412, 1998.
4.
VanhoeferU., HarstrickA., AchterrathW.: Irinotecan in the treatment of colorectal cancer: clinical overview.J Clin Oncol, 19: 1501–1518, 2001.
5.
PozzoC., PyrhönenS., BodrogiI.: A randomized phase II trial assessing irinotecan (IRI) and 5FU/folinic acid (LV), “Mayo regimen”, in first line palliative chemotherapy patients with metastatic colorectal cancer.Eur J Cancer,35(suppl 4): S70 (abstr), 1999.
6.
FalconeA., Di PaoloA., MasiG.: Sequence effect of irinotecan and 5-fluorouracil treatment on pharmacokinetics and toxicity in chemotherapy-naive metastatic colorectal cancer patients.J Clin Oncol, 19: 3456–3462, 2001.
7.
SaltzL.B., CoxJ.V., BlankeC.: Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer.N Engl J Med, 343: 905–914, 2000.
8.
DouillardJ.Y., CunninghamD., RothA.D.: Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicenter randomized trial.Lancet, 355: 1041–1047, 2000.
9.
KohneC.H., Van CutsemE., WilsJ.A.: Irinotecan improves the activity of the AIO regimen in metastatic colorectal cancer: results of EORTC GI Group study 40986.Proc ASCO, 22: 254 (abstr), 2003.
10.
GoldbergR.M., SargentD.J., MortonR.F.: A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer.J Clin Oncol, 22: 23–30, 2004.
11.
TournigandC., AndreT., AchilleE.: FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study.J Clin Oncol, 22: 229–237, 2004.
12.
GrotheyA., SargentD., GoldbergR.M.: Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucov-orin, irinotecan, and oxaliplatin in the course of treatment.J Clin Oncol, 22: 1209–1214, 2004.
13.
FalconeA., MasiG., AllegriniG.: Biweekly chemotherapy with oxaliplatin, irinotecan, infusional fluorouracil, and leucovorin: a pilot study in patients with metastatic colorectal cancer.J Clin Oncol, 20: 4006–4014, 2002.
14.
MasiG., AllegriniG., CupiniS.: First line treatment of metastatic colorectal cancer with irinotecan, oxaliplatin and 5-fluorouracil/leucovorin (FOLFOXIRI): results of phase II study with a simplified biweekly schedule.Ann Oncol, 15: 1766–1772, 2004.
15.
SoepenbergO., DumezH., VerweijJ.: Phase I and pharmacokinetic study of oral irinotecan given once daily for 5 days every 3 weeks in combination with capecitabine in patients with solid tumors.J Clin Oncol, 23: 889–898, 2005.
16.
BornerM.M., BernhardJ., DietrichD.: A randomized phase II trial of capecitabine and two different schedules of irinotecan in first-line treatment of metastatic colorectal cancer: efficacy, quality-of-life and toxicity.Ann Oncol, 16: 282–288, 2005.
17.
BajettaE., Di BartolomeoM., MarianiL.: Randomized multicenter phase II trial of two different schedules of irinotecan combined with capecitabine as first-line treatment in metastatic colorectal carcinoma.Cancer, 100: 279–287, 2004.
18.
CunninghamD., HumbletY., SienaS.: Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer.N Engl J Med, 351: 337–345, 2004.
19.
HurwitzH., FehrenbacherL., NovotnyW.: Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.N Engl J Med, 350: 2335–2342, 2004.
